Amneal has received approval for its second US biosimilar in the form of the mAbxience-developed Alymsys rival to Avastin. The product represents just the third biosimilar version of bevacizumab to be approved in the US.
Amneal Pharmaceuticals has received approval for its second biosimilar in the US, in the form of the Alymsys (bevacizumab-maly) rival to Avastin on which it has partnered with developer mAbxience.
Along with its recently-approved Releuko (filgrastim-ayow) version of Neupogen and its filed but not yet approved pegfilgrastim rival to Neulasta – for which Amneal expects an approval this year – the bevacizumab product forms a major part of the firm’s push into biosimilars
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.
With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.
Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.
